HTBX
Income statement / Annual
Last year (2021), Heat Biologics, Inc.'s total revenue was $2.11 M,
a decrease of 28.33% from the previous year.
In 2021, Heat Biologics, Inc.'s net income was -$35.40 M.
See Heat Biologics, Inc.’s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
FY-2015
|
FY-2014
|
FY-2013
|
FY-2012
|
| Period Ended |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
12/31/2015 |
12/31/2014 |
12/31/2013 |
12/31/2012 |
| Operating Revenue |
$2.11 M
|
$2.95 M
|
$3.05 M
|
$5.79 M
|
$1.52 M
|
$341,643.00
|
$0.00
|
$0.00
|
$0.00
|
$3,110.00
|
| Cost of Revenue |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
| Gross Profit |
$2.11 M |
$2.95 M |
$3.05 M |
$5.79 M |
$1.52 M |
$341,643.00 |
$0.00 |
$0.00 |
$0.00 |
$3,110.00 |
| Gross Profit Ratio |
1 |
1 |
1 |
1 |
1 |
1 |
0 |
0 |
0 |
1 |
| Research and Development
Expenses |
$18.82 M
|
$12.94 M
|
$13.01 M
|
$16.23 M
|
$8.27 M
|
$9.33 M
|
$2.60 M
|
$2.86 M
|
$2.74 M
|
$902,938.00
|
| General & Administrative
Expenses |
$16.83 M
|
$15.00 M
|
$9.43 M
|
$7.03 M
|
$0.00
|
$4.14 M
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling & Marketing
Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General &
Administrative Expenses |
$16.83 M
|
$15.00 M
|
$9.43 M
|
$7.03 M
|
$0.00
|
$4.14 M
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Other Expenses |
$1.88 M |
$0.00 |
$0.00 |
$0.00 |
$6.37 M |
$0.00 |
$18.43 M |
$9.33 M |
$3.83 M |
$1.44 M |
| Operating Expenses |
$37.53 M |
$27.94 M |
$22.44 M |
$23.26 M |
$14.64 M |
$13.47 M |
$21.02 M |
$12.19 M |
$6.56 M |
$2.35 M |
| Cost And Expenses |
$37.53 M |
$27.94 M |
$22.44 M |
$23.26 M |
$14.64 M |
$13.47 M |
$21.02 M |
$12.19 M |
$6.56 M |
$2.35 M |
| Interest Income |
$815,316.00 |
$566,718.00 |
$431,824.00 |
$265,752.00 |
$22,167.00 |
$31,142.00 |
$66,000.00 |
$40,570.00 |
$10,068.00 |
$2.00 |
| Interest Expense |
$127,742.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$549,403.00 |
$364,000.00 |
$73,354.00 |
$79,119.00 |
$101,086.00 |
| Depreciation &
Amortization |
-$127,742.00
|
$333,152.00
|
$232,506.00
|
$237,318.00
|
$134,084.00
|
$132,077.00
|
$116,000.00
|
$66,895.00
|
$6,348.00
|
$2,587.00
|
| EBITDA |
-$35.55 M
|
-$25.72 M
|
-$19.74 M
|
-$16.48 M
|
-$12.52 M
|
-$11.89 M
|
-$19.82 M
|
-$11.65 M
|
-$8.63 M
|
-$2.32 M
|
| EBITDA Ratio |
-16.82 |
-8.72 |
-6.47 |
-2.84 |
-8.24 |
-34.81 |
0 |
0 |
0 |
-744.86 |
| Operating Income Ratio
|
-16.76
|
-8.86
|
-6.8
|
-3.1
|
-8.78
|
-38.42
|
0
|
0
|
0
|
-753.27
|
| Total Other
Income/Expenses Net |
-$127,742.00
|
-$257,027.00
|
$406,267.00
|
$383,532.00
|
$123,443.00
|
$152,520.00
|
-$100,000.00
|
-$56,284.00
|
-$45,223.00
|
-$108,341.00
|
| Income Before Tax |
-$35.55 M |
-$26.38 M |
-$20.34 M |
-$17.58 M |
-$13.22 M |
-$12.97 M |
-$21.12 M |
-$12.24 M |
-$6.61 M |
-$2.45 M |
| Income Before Tax Ratio
|
-16.82
|
-8.95
|
-6.67
|
-3.03
|
-8.7
|
-37.98
|
0
|
0
|
0
|
-788.11
|
| Income Tax Expense |
-$145,974.00 |
-$257,027.00 |
$45,178.00 |
-$985,488.00 |
-$809,540.00 |
$701,923.00 |
$264,000.00 |
$17,070.00 |
$33,896.00 |
-$7,255.00 |
| Net Income |
-$35.40 M |
-$26.05 M |
-$20.02 M |
-$15.73 M |
-$11.84 M |
-$12.57 M |
-$20.30 M |
-$11.79 M |
-$8.71 M |
-$2.42 M |
| Net Income Ratio |
-16.76 |
-8.84 |
-6.57 |
-2.72 |
-7.79 |
-36.8 |
0 |
0 |
0 |
-778.2 |
| EPS |
-1.41 |
-1.63 |
-4.21 |
-6.3 |
-21.56 |
-49.4 |
-174.92 |
-126.18 |
-160.61 |
-90.87 |
| EPS Diluted |
-1.41 |
-1.63 |
-4.21 |
-6.3 |
-21.56 |
-49.4 |
-174.92 |
-126.18 |
-160.61 |
-90.87 |
| Weighted Average Shares
Out |
$25.14 M
|
$15.98 M
|
$4.75 M
|
$2.50 M
|
$549,334.00
|
$254,550.00
|
$116,022.00
|
$93,430.00
|
$54,240.00
|
$26,633.00
|
| Weighted Average Shares
Out Diluted |
$25.14 M
|
$15.98 M
|
$4.75 M
|
$2.50 M
|
$549,334.00
|
$254,550.00
|
$116,022.00
|
$93,430.00
|
$54,240.00
|
$26,633.00
|
| Link |
|
|
|
|
|
|
|
|
|
|
